Rat and Calf Thioredoxin Reductase Are Homologous to Glutathione Reductase with a Carboxyl-terminal Elongation Containing a Conserved Catalytically Active Penultimate Selenocysteine Residue*

Liangwei ZhongDagger , Elias S. J. ArnérDagger , Johanna Ljung, Fredrik Åslund, and Arne Holmgren§

From the Medical Nobel Institute for Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

We have determined the sequence of 23 peptides from bovine thioredoxin reductase covering 364 amino acid residues. The result was used to identify a rat cDNA clone (2.19 kilobase pairs), which contained an open reading frame of 1496 base pairs encoding a protein with 498 residues. The bovine and rat thioredoxin reductase sequences revealed a close homology to glutathione reductase including the conserved active site sequence (Cys-Val-Asn-Val-Gly-Cys). This also confirmed the identity of a previously published putative human thioredoxin reductase cDNA clone. Moreover, one peptide of the bovine enzyme contained a selenocysteine residue in the motif Gly-Cys-SeCys-Gly (where SeCys represents selenocysteine). This motif was conserved at the carboxyl terminus of the rat and human enzymes, provided that TGA in the sequence GGC TGC TGA GGT TAA, being identical in both cDNA clones, is translated as selenocysteine and that TAA confers termination of translation. The 3'-untranslated region of both cDNA clones contained a selenocysteine insertion sequence that may form potential stem loop structures typical of eukaryotic selenocysteine insertion sequence elements required for the decoding of UGA as selenocysteine. Carboxypeptidase Y treatment of bovine thioredoxin reductase after reduction by NADPH released selenocysteine from the enzyme with a concomitant loss of enzyme activity measured as reduction of thioredoxin or 5,5'-dithiobis(2-nitrobenzoic acid). This showed that the carboxyl-terminal motif was essential for the catalytic activity of the enzyme.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Thioredoxin reductase is a dimeric enzyme with a redox-active disulfide and an FAD in each monomer, and it is a member of a larger family of pyridine nucleotide-disulfide oxidoreductases, which includes the closely related enzymes lipoamide dehydrogenase, glutathione reductase, trypanothione reductase, and mercuric ion reductase (1). Thioredoxin reductase (TrxR)1 catalyzes the NADPH-dependent reduction of the active site disulfide in oxidized thioredoxin (Trx-S2) to give a dithiol in reduced thioredoxin (Trx-(SH)2).
<UP>NADPH</UP>+<UP>H</UP><SUP>+</SUP>+<UP>Trx-S</UP><SUB>2</SUB> <LIM><OP><ARROW>→</ARROW></OP><LL>←</LL></LIM> <UP>NADP</UP><SUP><UP>+</UP></SUP>+<UP>Trx-</UP>(<UP>SH</UP>)<SUB>2</SUB>
<UP><SC>Reaction</SC> 1</UP>
Thioredoxin is a ubiquitous 12-kDa protein with a large number of biological activities (1-6). Reduced thioredoxin is a powerful protein-disulfide reductase catalyzing either electron transport to ribonucleotide reductase and other reductive enzymes or redox regulation of enzymes and transcription factors. Secreted thioredoxin has cytokine-like effects on certain mammalian cells (2-7).

Thioredoxin reductase from Escherichia coli has been extensively characterized (1), and a high resolution x-ray structure shows surprisingly large differences from the other members of the pyridine nucleotide-disulfide oxidoreductase family (8, 9). Thus, the subunits of about 35 kDa are smaller than the ~50-kDa subunits present in glutathione reductase from all species. Furthermore, the active site cysteine residues of E. coli TrxR are located in the NADPH domain and separated by two amino acids (Cys-Ala-Thr-Cys), in comparison with the active site in glutathione reductase, which is Cys-Val-Asn-Val-Gly-Cys and located in the FAD domain, suggesting convergent evolution (9). The structural features of TrxR from E. coli with a high specificity for its homologous Trx are also typical for TrxR from prokaryotes, lower eukaryotes like yeast, or plants (1, 8-10).

It has long been known that TrxR from mammalian cells has very different properties compared with that from E. coli and lower organisms (2-4). The enzymes from calf liver and thymus and rat liver were first purified to homogeneity and showed subunits with an Mr of 58,000 (11, 12). The mammalian thioredoxin reductases including that of human placenta (13) are not only larger than the E. coli enzyme but have a very different and wide substrate specificity. Thus, the mammalian enzymes will reduce thioredoxins from different species (11), several low molecular weight disulfide substrates including DTNB used in assays (11, 12), or lipoic acid (14) as well as other nondisulfide substrates including selenodiglutathione (15), selenite (16), alloxan (17), or (most surprisingly) lipid hydroperoxides (18). The wide substrate specificity indicates an unusual structure of the active site, which is also demonstrated by the inhibition of mammalian TrxR by several drugs in clinical use including antitumor quinones (19, 20), nitrosoureas (21), or 13-cis-retinoic acid (22). Furthermore, 1-chloro-2,4-dinitrobenzene selectively inactivates the reduced form of mammalian TrxR (23).

Recently, two proteins from transformed human cells having thioredoxin reductase activity, a 55-kDa subunit enzyme from a Jurkat T-cell line (24) and a 57-kDa subunit protein from a lung adenocarcinoma cell line (25), were shown to contain selenocysteine. A peptide sequence from the protein purified from the human T cell line (24) agreed with a putative human placental TrxR cDNA sequence showing homology to glutathione reductase but not prokaryotic TrxR (26). The putative human placental cDNA clone did not give any active enzyme, since expression in E. coli resulted in a protein of the correct Mr, which, however, did not incorporate FAD (26).

We have sequenced peptides from calf thymus and liver TrxR. Together with the sequence of the translated open reading frame of a rat TrxR cDNA clone, the close structural homology to glutathione reductase was evident, and the earlier published putative human cDNA clone could be confirmed. We found that a carboxyl-terminal motif containing cysteine and selenocysteine was conserved among human, rat, and bovine TrxR, and we present evidence that the carboxyl terminus is essential for the catalytic activity of the enzyme. Preliminary results have been reported (27).

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials

2',5'-ADP-Sepharose and Q Sepharose were from Amersham Pharmacia Biotech. DL-Selenocystine was from Serva (Heidelberg). Trypsin came from Promega, and endoproteinase Lys-C was from Wako. Carboxypeptidase Y was kindly provided by Prof. Viktor Mutt (Karolinska Institutet, Stockholm). Recombinant human Trx was prepared as described (28). Chemicals for peptide sequencing were delivered by Perkin-Elmer, and chemicals for DNA sequencing were delivered by Amersham Pharmacia Biotech. All additional chemicals were of analytical grade or better, and sources have been given in previous publications (11, 12, 17).

Purification of Thioredoxin Reductase

Calf liver and thymus were obtained from a local slaughter house and stored frozen at -20 °C. TrxR was purified by the method described earlier (11, 12) with some modifications summarized as follows. Crude extract was acidified to pH 5.0, the neutralized supernatant was fractionated with solid (NH4)2SO4, and proteins precipitated between 40 and 80% saturation were dissolved in 50 mM Tris-HCl, 1 mM EDTA, pH 7.5 (TE buffer). Following extensive dialysis, the sample was incubated with 2 mM DTT and applied to a column of DEAE-cellulose in TE buffer, which was eluted with a linear gradient of 0-0.3 M KCl. Fractions containing TrxR activity were pooled, dialyzed against TE buffer, and applied to a 2',5'-ADP-Sepharose column, which was eluted with a linear gradient of 0-0.6 M NaCl. Fractions from this chromatography that contained TrxR activity were dialyzed and applied to a Q-Sepharose column eluted with a linear 0-0.4 M NaCl gradient. The enzyme was finally dialyzed against TE buffer and applied to an omega -aminohexyl-agarose column eluted with a 0-0.7 M NaCl gradient in TE buffer. This purification scheme typically resulted in 2.5 mg of homogeneous enzyme with a specific activity in DTNB reduction (3, 12) of more than 1000 A412/min/mg from 1 kg of tissue, i.e. more than 22 units/mg (12).

Selenium Content

The selenium content of TrxR was determined on homogenous preparations from calf thymus or human placenta (28) using 60 µg of enzyme. The method used was graphite furnace atomic absorption spectrophotometry with Zeeman background correction using a Perkin-Elmer 5000 instrument, with a commercial selenium standard and background subtraction from buffer as described by Björkman et al. (29). The generous help of Birger Lind (Institute of Environmental Medicine, Karolinska Institute) is acknowledged.

NH2-terminal Sequencing

Thioredoxin reductase (35 µg) was dissolved in 50 µl of 6 M guanidine hydrochloride, 0.1 M Tris-HCl, 2 mM EDTA, pH 8.0, and reduced in 5 mM DTT for 60 min at 37 °C. Then sulfhydryl groups were carboxymethylated in 100 mM iodoacetic acid overnight at room temperature in the dark, followed by desalting on Sephadex G-25 in TE buffer prior to automated Edman degradation using a Procise Protein Sequencer (Applied Biosystems). This revealed a blocked NH2 terminus. In a separate experiment, however, the enzyme was desalted only in distilled water and then incubated at room temperature for 24 h in 30% acetic acid prior to Edman degradation, which in that case gave an NH2-terminal sequence as described.

Analysis of Peptides from TrxR Single-labeled with 4-Vinylpyridine

Bovine TrxR (50 µg) was reduced and denatured by incubation at room temperature for 15 min in 10 mM DTT, 3 M guanidine hydrochloride, 25 mM Tris-HCl, 0.5 mM EDTA, pH 7.5. Subsequently, alkylation was carried out by either the addition of 1 µl of vinylpyridine to 100 µl of reduced and denatured TrxR or by the addition of neutralized iodoacetic acid to a final concentration of 50 mM. The alkylation reactions were allowed to proceed during 2 h in the dark. Reduced and alkylated protein was desalted on a fast desalting (Sephadex G-25) column with the SMART system (Amersham Pharmacia Biotech) using TE buffer as eluent and was then concentrated by centrifugation in a Microsep concentrator (Filtron, 10-kDa cut-off). Peptides were generated upon 10-fold dilution in 100 mM NH4HCO3, pH 8.0, and incubation at 37 °C overnight with either trypsin or lysine protease at a ratio of 1:10 (protease:TrxR), in the presence of 1 M guanidine hydrochloride. Peptides were separated using the Amersham Pharmacia Biotech SMART system with a C2/C18 Sephasil column and a linear gradient of 5-80% acetonitrile in water containing 0.1% trifluoroacetic acid during 90 min at a flow rate of 50 µl/min. Eluted peptides were detected at 215, 280, and 254 nm and fractionated by automatic peak detection using the absorbance at 215 nm. Peptides were then analyzed by peptide sequencing on a Procise Protein Sequencer (Applied Biosystems) according to the manufacturer's instructions.

Analysis of Peptides from TrxR Labeled with Iodoacetic Acid Followed by 4-Vinylpyridine after NADPH Incubation

TrxR (150 µg) was dissolved in 80 mM Tris-HCl, 0.5 M guanidine hydrochloride, 0.2 mM EDTA, pH 8.0, for 30 min at room temperature. The SH groups were carboxymethylated using 300 nmol of iodoacetic acid overnight in the dark at room temperature. The carboxymethylated enzyme was desalted by gel filtration (Fast desalting PC 3.2/10 column). To this protein solution was added 720 nmol of NADPH. After an additional 15 min of incubation, the nascent SH groups were derivatized with 250 nmol of 4-vinylpyridine for 4 h at room temperature in the dark. The mixture was desalted again, and 5 µl of endoproteinase Lys-C (2 µg/µl) was added. The digestion was carried out at 37 °C overnight. After the addition of another 5 µl of endoproteinase Lys-C and an additional incubation for 2 h, the resulting peptides were separated on a µRPC (C2/C18; SC2.1/10) column with the SMART system (Amersham Pharmacia Biotech). The column was eluted with a linear gradient from 0 to 80% acetonitrile in 0.1% trifluoroacetic acid over 190 min at a flow rate of 0.1 ml/min. The Edman procedure was used for analyzing the peptides on a Procise Protein Sequencer (Applied Biosystems).

Carboxypeptidase Y Treatment of TrxR

Carboxypeptidase Y (1 mg/ml) was dissolved in 10 mM sodium phosphate buffer, pH 7.0, containing 1 mM EDTA and stored for no more than 24 h at -20 °C prior to use to avoid autodigestion. EDTA was included to inhibit possible contaminant activities of yeast protease A or aminopeptidase.

Assay of TrxR Activity-- TrxR activity was determined as the NADPH-dependent reduction of 5 mM DTNB or 5 µM human Trx and insulin disulfides by previously developed methods (12). One unit of TrxR activity is defined as the oxidation of 1 µmol of NADPH min-1 at 25 °C (12).

Inactivation with Carboxypeptidase Y-- To determine the time course of TrxR inactivation by carboxypeptidase Y, 2.7 µg of calf liver TrxR was preincubated with 8 nmol of NADPH in 10 mM sodium phosphate, 1 mM EDTA, pH 7.0, at room temperature for 30 min in a total volume of 10 µl. To the reduced enzyme, 1 µl of carboxypeptidase Y (1 mg/ml) was added, and the sample was incubated at 37 °C. Aliquots (2.5 µl) were removed at various times and assayed for catalytic activity. Control incubations were identical except that carboxypeptidase and/or NADPH was not included.

Analysis of Released Amino Acids-- Calf liver TrxR (108 µg) was diluted in 10 mM sodium phosphate, 1 mM EDTA, pH 7.0, with 320 nmol of NADPH in a final volume of 380 µl. After preincubation for 30 min at room temperature, 20 µl of carboxypeptidase Y (1 mg/ml) was added, and the mixture was incubated at 37 °C. After 30 min, 2 h, 4 h, and 24 h, 60-µl aliquots were withdrawn and stored at -20 °C. To monitor the effect of digestion, 0.5-µl aliquots from each sample were taken for analysis of TrxR activity, as described above. This showed that no more than 60% inactivation had occurred up to 24 h of incubation, and therefore an additional 10-µl carboxypeptidase Y was added to each 60-µl aliquot, and incubation was continued at 37 °C, for each of the samples for the same time period as before the second addition of carboxypeptidase Y, i.e. 30 min, 2 h, 4 h, and 24 h. These incubations were again terminated by moving the samples to -20 °C. For analysis of amino acids released after carboxypeptidase Y digestion, protein was removed from the low molecular weight fraction. To do this and to stop further digestion, samples were thawed and centrifuged in Millipore Ultrafree-MC filters (10-kDa cut-off). The filtrates containing buffer, salts, and released amino acid residues were lyophilized, 7 µl of 0.5 M DTT was added, and then the samples were subjected to amino acid analysis with ion exchange chromatography and ninhydrin derivatization using an Amersham Pharmacia Biotech 4151 Alpha Plus analyzer. Standard amino acids were analyzed under the same conditions.

Cloning and Sequencing of Rat TrxR cDNA

Using part of a bovine TrxR peptide with a unique amino acid sequence (KVMVLDFVTPTPLGTRCG), a rat cDNA clone was identified in GenBankTM searches as coding for rat thioredoxin reductase,2 originally derived from rat neuroblastoma cells treated with nerve growth factor (31), and only partially sequenced. The clone was obtained from the Institute for Genomic Research (31), and to determine insert size and end sequences of the insert, M13 universal and M13 reverse oligonucleotide primers were used for polymerase chain reaction amplification of the insert as well as initial sequence reactions. Sequence determination of the complete insert was carried out using an automated laser fluorescent DNA sequencer (A.L.F., Amersham Pharmacia Biotech) according to protocols from the manufacturer, with subsequent primers based on the new sequence data.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Selenium Content of Mammalian Thioredoxin Reductase-- We started structural studies of bovine (11) and rat (12) thioredoxin reductase several years ago with the aim of cloning the enzyme and to explain its unique structural characteristics (27).

Due to the recent report of selenium in TrxR isolated from transformed human cells (24), we analyzed TrxR, classically purified from calf thymus (11) to determine if this also contained selenium. We found that TrxR from calf thymus as well as human placenta contained 0.6 selenium atoms/58-kDa subunit, which was less than the corresponding value of 0.74 selenium atoms (24) or, as recently reported for TrxR from human placenta, 0.93 selenium atoms (32) per subunit. Since we found that human and calf TrxR contained the same amount of selenium, we continued our ongoing study of the calf enzyme, with a special emphasis on the structure of the enzyme and the significance of the selenium content for its catalytic properties.

Bovine TrxR Peptide Sequences-- Sequence analysis of reduced and carboxymethylated TrxR from calf liver revealed a blocked NH2 terminus. Interestingly, following incubation in 30% acetic acid, an NH2-terminal sequence KDLPEPYDYDLIIIGGGSGGYD could be determined, which we later found starts four residues after the initiating methionine based on alignments to human and rat TrxR (see below).

Initial sequence information of TrxR purified from calf thymus was obtained by cleavage of the enzyme with trypsin or endoproteinase Lys-C followed by reverse phase HPLC and sequence determination of the resulting peptides. In total, we determined the sequence of 23 peptides, covering in total 364 reliable amino acid residues. None of these peptide sequences showed high homology with earlier determined thioredoxin reductase sequences from lower organisms. However, the close homology with glutathione reductase was evident for several of the peptides, especially to a probable glutathione reductase from C. elegans3 that is probably a thioredoxin reductase. The peptides also showed very high homology to the deduced amino acid sequence of a putative cDNA clone of human placental TrxR (26), thereby confirming this putative sequence, since all peptides were derived from purified native and enzymatically active thioredoxin reductase.

In a separate experiment, we selectively derivatized residues of calf liver TrxR that were reduced by NADPH. This was done by carboxymethylation of sulfhydryl groups in the oxidized enzyme with unlabeled iodoacetic acid prior to incubation with NADPH and with subsequent alkylation of NADPH-dependently reduced residues with 4-vinylpyridine. This modified enzyme was then digested with endoproteinase Lys-C, and peptides were separated by reverse phase HPLC. Using this approach, several peptides labeled with 4-vinylpyridine could be detected by increased absorption at 254 nm (Fig. 1). One of these peptides (Fig. 1, peak A) had the determined sequence VMVLDFVTPTPLGTRCGLGGTCVNVGCIP. The COOH-terminal part of this peptide is identical to the active site of glutathione reductase, Cys-Val-Asn-Val-Gly-Cys (1). Both Cys residues had been derivatized with 4-vinylpyridine, indicating that only after incubation with NADPH were the nascent sulfhydryl groups susceptible to alkylation. In the oxidized enzyme, a disulfide would be present. The unique NH2-terminal part of this peptide, not homologous to glutathione reductase or other enzymes of this family, was subsequently used to identify a rat TrxR cDNA clone (see below).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Separation of bovine TrxR peptides generated with endoproteinase Lys-C after selective 4-vinylpyridine labeling of amino acid residues reduced with NADPH. Amino acid residues of calf liver TrxR accessible for alkylation only after incubation with NADPH were labeled with 4-vinylpyridine as described in the text. The enzyme was treated with endoproteinase Lys-C, resulting peptides were separated using reverse phase chromatography, and pyridylethylated peptides were identified by an increased absorbance at 254 nm. Peptide C was the later identified carboxyl-terminal peptide and peptide A was the peptide containing a sequence homologous with the active center of glutathione reductase (see Table I). The dashed line shows the gradient as a percentage of buffer B (0.1% trifluoroacetic acid in acetonitrile), and absorbance at 215, 280, and 254 nm was as indicated in the figure. For further experimental details, see the text. The high absorbance at 254 nm appearing after 100 min was buffer-related.

A second peptide selectively labeled with 4-vinylpyridine upon incubation with NADPH (Fig. 1, peak C) had the sequence RSGGNILQTGCXG, where X represents a pyridylethylated uncommon amino acid, eluting immediately after the standard for proline in the amino acid sequencing. The cysteine immediately before X was also pyridylethylated, showing that both this cysteine residue and the X residue were made accessible for alkylation by incubation of the enzyme with NADPH.

The different determined amino acid sequences of bovine TrxR peptides are summarized in Table I.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Determined amino acid sequences of bovine TrxR peptides

Effects of Carboxypeptidase Y on Calf Liver TrxR-- Since the subunit of TrxR has the COOH-terminal sequence -Gly-Cys-SeCys-Gly, we wanted to study the effect of carboxypeptidase digestion. The effects of NADPH and carboxypeptidase Y with or without NADPH present on TrxR activity at 37 °C are shown in Fig. 2A. The oxidized TrxR was resistant to attack of carboxypeptidase Y, and only reduced TrxR lost activity after incubation with carboxypeptidase Y. Controls showed that although incubation with NADPH was a prerequisite for inactivation with carboxypeptidase Y, solely incubation with NADPH did not inactivate the enzyme (Fig. 2A). The ability of TrxR to reduce Trx seemed more susceptible to carboxypeptidase Y treatment than the capacity to reduce DTNB (Fig. 2B), the latter compound used as a substrate in assays of the enzyme (3, 11).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Catalytic activity of calf liver TrxR upon treatment with carboxypeptidase Y. A, calf liver TrxR was preincubated for 30 min at room temperature with or without NADPH at pH 7.0 in 10 mM sodium phosphate containing 1 mM EDTA. Then the enzyme was incubated for another 4 h at 37 °C with or without the addition of carboxypeptidase Y, as indicated at the bottom of panel A. Enzyme activity was then measured using DTNB or Trx-coupled insulin reduction and is presented as percentage of control. B, calf liver TrxR was preincubated for 30 min at room temperature with NADPH at pH 7.0 in 10 mM sodium phosphate containing 1 mM EDTA. Then carboxypeptidase Y was added, and incubation was continued at 37 °C. At the indicated time points, aliquots were withdrawn and examined for enzymatic activity using either DTNB or human Trx coupled to insulin, as indicated in the figure. Results are presented as percentage of control activity at 0 h of incubation.

Data obtained after amino acid analysis of residues released from calf liver TrxR upon carboxypeptidase Y treatment are presented in Fig. 3. After 30 min of digestion, carboxypeptidase Y had released free Gly and SeCys. The release of Gly continued to increase, consistent with the presence of more than one Gly residue in the carboxyl-terminal region. An additional amino acid residue could be detected that increased with time but did not co-elute with any of the amino acids known to be present at the carboxyl terminus of the enzyme (Fig. 3, peak X).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   Amino acid analysis of residues released upon incubation of calf liver TrxR with carboxypeptidase Y. Calf liver TrxR (108 µg) was preincubated for 30 min in a total volume of 380 µl with NADPH (320 nmol) at pH 7.0 in 10 mM sodium phosphate containing 1 mM EDTA. Then carboxypeptidase Y (20 µg) was added, and aliquots (60 µl) were taken at the indicated time points. To each aliquot, additional carboxypeptidase Y (10 µg) was added for a second incubation for the indicated time points. Then proteins were removed by centrifugation using Millipore Ultrafree-MC filters (10-kDa cut-off). The filtrate containing water, salts, and released amino acids was lyophilized, solubilized in 7.0 µl of 0.5 M DTT, and subjected to amino acid analysis with ion exchange chromatography and ninhydrin derivatization. Peaks were compared with standards representing the expected amino acids to be released, as shown in the figure.

Lack of Covalent Bonds between the Subunits in the Oxidized Enzyme-- Analysis of the oxidized form of TrxR (12) with nonreducing SDS-polyacrylamide gel electrophoresis showed that the enzyme migrated as a protein of Mr ~58,000 with no detectable species of higher molecular weight (not shown), demonstrating that in the oxidized enzyme, no intermolecular covalent bonds between the subunits were present (which would migrate at about 116,000 or higher in nonreducing SDS-polyacrylamide gel electrophoresis).

Cloning and Sequencing of a Rat TrxR cDNA Clone-- The unique NH2-terminal part of the bovine peptide containing the glutathione reductase active site motif (KVMVLDFVTPTPLGTRCG; see above) was used in data base homology searches, which identified a rat EST cDNA clone2 as most likely encoding rat TrxR. This cDNA clone was isolated by expressed sequence tag analysis of differential gene expression upon treatment of neuroblastoma cells with nerve growth factor (31) and had been only partially sequenced.

Analysis of the rat cDNA clone revealed a size of the insert of more than 2 kilobase pairs, of which we subsequently determined the full sequence. The entire rat clone was 2193 nucleotides long and contained an open reading frame of 1497 nucleotides and 568-nucleotide-long 3'-untranslated region ending with an 18-nucleotide-long poly(A) tail. The rat cDNA sequence, except for the first 59 nucleotides, showed a high homology to the published putative human TrxR cDNA sequence (26). Nucleotides corresponding roughly to nucleotides 1-370 and 2505-3800 in the human sequence were missing in the rat cDNA clone, explaining its smaller size, while the full open reading frame and the part of the 3'-UTR containing a SECIS element (see below) was intact in the rat cDNA clone (Fig. 4).


View larger version (73K):
[in this window]
[in a new window]
 
Fig. 4.   Nucleotide sequence alignment of rat and human cDNA clones. The sequence of the rat TrxR cDNA clone (lower sequence, this work) is aligned with that of the previously published (26) human TrxR cDNA clone (upper sequence). Both nucleotide sequences contain an open reading frame starting with ATG and ending with TGAGGTTAA (indicated by small boxes in the alignment). In the 3'-untranslated region, potential SECIS elements (40) could be identified in both sequences (large box), shown in further detail in Fig. 5. Identical nucleotides between the two sequences are indicated by dots. The 5'- and 3'-ends of the human cDNA sequence are not shown.

The bovine peptide sequence RSGGNILQTGCXG with experimental confirmation of X as selenocysteine (see above) corresponded to the COOH-terminal end of the translated open reading frame of the rat or human cDNA clones using TGA as a codon for incorporation of selenocysteine. The mechanisms for incorporation of selenocysteine in mammalian proteins are not yet fully clarified. However, it is clear that a TGA codon is not sufficient genetic information for encoding SeCys, but in addition, selenocysteine insertion sequences (SECIS elements) in the 3'-UTR of several mammalian selenoprotein mRNAs have been identified (34-39). In two recent reports (39, 40), consensus sequences and folding patterns of mammalian SECIS elements were proposed. We therefore examined the 3'-UTR of the human and rat thioredoxin reductase cDNA clone sequences and a typical SECIS element could be identified in both sequences, at approximately the same distance from the TGA codon (large box in Fig. 4). Although somewhat different from each other, the SECIS elements of both rat and human TrxR could form potential stem-loop structures, which agreed well with the eukaryotic SECIS folding structures proposed by both Low and Berry (39) and Walczak et al. (40). This is shown in Fig. 5.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Proposed SECIS elements of rat and human TrxR. Shown in A is a potential secondary structure of the 3'-UTR of the rat TrxR nucleotide sequence, as predicted using the FOLD computer program (Genetics Computer Group). The region forming a probable SECIS element is indicated, and nucleotides corresponding to this region are boxed in the alignment of the human and rat TrxR cDNA sequences (large box in Fig. 4). Using manual folding, the probable SECIS elements of both rat and human TrxR could be folded to secondary structures in close resemblance to the consensus of eukaryotic SECIS elements proposed by Walczak et al. (40) (B), as well as the eukaryotic form II consensus SECIS element proposed by Low and Berry (39) (C). In the upper part of panels B and C, the basic features of the consensus SECIS elements are given, with conserved and essential nucleotides for SECIS function shown in boldface type, including the adenines in the loop or bulge, and the "quartet" or "base of stem" motif comprising non-Watson-Crick base pairing. The manually folded rat and human TrxR SECIS elements are shown below the schematic structures of the consensus SECIS elements, with starting and ending nucleotide numbers indicated corresponding to the cDNA clones (see large box in Fig. 4).

Homologies between Mammalian TrxR Amino Acid Sequences and Consensus with Other Members of the Enzyme Family-- Fig. 6 shows that the amino acid sequences determined from the bovine TrxR peptides had high homology to the translated open reading frames of the rat and human TrxR cDNA clone sequences, thereby conclusively confirming the identity of these clones. Due to the confirmation of SeCys in the carboxyl terminus of the bovine enzyme (Fig. 3) as well as the finding of SECIS elements in the rat and human Trx cDNA sequences (Fig. 5), TGA is proposed to translate as a SeCys residue in Fig. 6. Shown in Fig. 6 is also the high homology between the mammalian TrxR sequences and human glutathione reductase.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 6.   Alignment of rat, bovine, and human TrxR amino acid sequences and comparison with human glutathione reductase. Shown is the amino acid translation of the open reading frame in the rat TrxR cDNA sequence (rTrxR), with residues numbered to the right starting with the initial methionine. Amino acids of the translated human TrxR cDNA (hTrxR) sequence (26) are shown below the rat sequence, and the determined peptides from bovine TrxR (bTrxR) are shown above the rat sequence. Residues identical among the three species are boxed. Below the three mammalian thioredoxin reductase sequences is given the amino acid sequence of human glutathione reductase (hGR). Residues that are identical among human glutathione reductase and the mammalian thioredoxin reductases are indicated with * (+ for partial identity). Note that the highest homology is found in the last third of the sequences, corresponding to the interface region, where the highest homology is found also between other enzymes of the glutathione reductase family (1). Amino acids within the first 300 amino acids in glutathione reductase that are conserved in the consensus sequences of lipoamide dehydrogenase, trypanothione reductase, and mercuric reductase (1) are indicated with open triangles. The initial three amino acids of the rat TrxR shown in italics indicate a potential N-glycosylation motif. The boldface U497 designates the selenocysteine residue.

The mammalian thioredoxin reductases contained all of the features of conserved structure domains of glutathione reductase, i.e. FAD, pyridine nucleotide, central domain, and interface domain (1). The highest homology to glutathione reductase (indicated by * or + in Fig. 6) was in the interface region (i.e. within the last 150 amino acids) that governs the association of the two subunits in the dimeric holoenzyme. In alignments of glutathione reductase, lipoamide dehydrogenase, trypanothione reductase, and mercuric reductase, this is the region that displays the highest sequence conservation among these enzymes (1), which thereby holds true for mammalian thioredoxin reductase as well. Williams (1) has indicated which residues among the first 300 amino acids in glutathione reductase that are conserved within the whole enzyme family. Out of these 36 conserved residues (Fig. 6, open triangles), only two were not conserved in the mammalian TrxR sequences (Ala130 and Ser295 in the rat enzyme). One interesting structural difference between the human and the rat predicted proteins is the consensus sequence for N-linked glycosylation (Asn-Asp-Ser) in the rat enzyme (Fig. 6). The significance of this is not known.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In this study, we found that a selenocysteine containing COOH-terminal motif (-Gly-Cys-SeCys-Gly-COOH) is conserved among rat, calf, and human TrxR and that both rat and human cDNA sequences carry consensus sequences in the 3'-UTR necessary for the proper incorporation of selenocysteine during translation of the mRNA. We have also shown that the carboxyl-terminal selenocysteine and cysteine residues are important for the catalytic activity of the enzyme.

TrxR from E. coli is by far the best characterized thioredoxin reductase. Differences between this enzyme and other pyridine nucleotide-disulfide oxidoreductases, such as glutathione reductase or lipoamide dehydrogenase, have been noted and discussed for quite some time, regarding differences in molecular weight, substrate specificities, and their primary and three-dimensional structures (1, 11, 12). The sequences presented here of both bovine TrxR peptides and a rat TrxR cDNA clone confirm the putative human TrxR cDNA sequence presented earlier (26), which so far has been the only mammalian TrxR sequence described.4 Clearly, mammalian TrxR, in contrast to E. coli TrxR, is structurally closely related to glutathione reductase and other members of this enzyme family. The motif in the NH2-terminal part of the enzyme containing the active site disulfide (Cys-Val-Asn-Val-Gly-Cys) is conserved, as well as the FAD domain and the NADPH binding regions, and there is a preservation of key residues important for the catalytic function (Fig. 6). In good agreement with this, a recent study of Williams and co-workers (32) using spectroscopic methods demonstrated the clear similarities in mechanism between human TrxR and glutathione reductase or lipoamide dehydrogenase, distinct from that of TrxR from E. coli. However, the selenocysteine-containing COOH-terminal part of mammalian TrxR is an addition to the basic structure that should play a significant role for the catalysis of TrxR distinct from that of glutathione reductase or lipoamide dehydrogenase, which lack this selenocysteine containing COOH-terminal elongation.

We found that the atomic absorption of TrxR purified from normal mammalian sources had a content of 0.6 selenium atom/58-kDa subunit (27), while Tamura and Stadtman (25) reported that TrxR from a human T cell line contained 0.74 selenium atoms/subunit. Recently, while this paper was in preparation, Williams, Becker, and co-workers (32, 41) found that the selenium content of human or mouse TrxR was higher than 0.9 selenium atoms/subunit. The discrepancies between these studies could be due to varying selenium content in the studied enzymes. It was recently demonstrated that selenium deficiency caused a decrease in TrxR activity to 4.5% of control in liver and 11% in kidney, while TrxR activity in brain was unaffected (42), indicating that selenium incorporation in TrxR may vary due to selenium availability as well as between tissues. Moreover, the selenium in SeCys residues of selenoproteins may be lost in handling of these proteins, such as acid treatment or by reduction and alkylation (43), and it could therefore be possible that some of the selenium of TrxR is lost during the purification procedures, thereby also possibly explaining the varying specific activity of different preparations of the enzyme. Further studies are required to clarify this.

The question has also been raised of possibly two distinct forms of TrxR from transformed human cells, which differed in heparin-binding and immunoreactivity but both having the same selenocysteine-containing COOH-terminal peptide sequence, identical to that which can be extrapolated from the earlier published putative human placental cDNA clone if TGA were to be translated as SeCys (44). Although isoenzymes may exist, it is now certain that TrxR with a penultimate COOH-terminal SeCys residue exists in rats, bovine tissues, and humans.

Incorporation of selenocysteine in eukaryotic selenoproteins requires the presence of specific selenocysteine insertion sequences (SECIS elements) in the 3'-UTR of the mRNA, forming a secondary structure that guides a specific tRNA, which together with accessory enzymes incorporates selenocysteine at the UGA codon (34-36, 39, 40). Recently, two different consensus models have been proposed for the sequence and secondary structure of eukaryotic (mammalian) SECIS elements based upon features in bovine, rat, and human glutathione peroxidases, selenoproteins P and W, and deiodinases (39, 40). Having access to two mammalian TrxR cDNA sequences, we could search for possible mammalian SECIS consensus elements in the 3'-UTR of these sequences. To determine probable folding patterns, the part corresponding to the 3'-UTR of the rat TrxR cDNA was subjected to computer prediction of secondary structure formation. This indicated a possible SECIS element-like stem-loop structure corresponding approximately to nucleotides 1855-1915. Using manual folding of this region of both the rat cDNA and the corresponding part of the human cDNA, typical SECIS consensus structures could be formed in agreement with both models proposed, although these models differed somewhat from each other (Fig. 5). The SECIS elements were situated approximately at the same distance from the TGA codon in both sequences (about 240 nucleotides). It should also be noted that 11-12 nucleotides were nonidentical between the rat and human sequences in this region, but these changes did not affect the possibility to predict folding of typical and essentially identical SECIS elements in both sequences (Fig. 5). No other obvious SECIS elements could be identified in the 3'-UTR of the rat or human TrxR cDNA sequences.

Based upon carboxypeptidase Y treatment of calf liver TrxR, several conclusions can be drawn regarding the character and function of the selenocysteine residue. The oxidized enzyme was resistant to cleavage, and only upon prior incubation with NADPH was the activity of the enzyme impaired by incubation with carboxypeptidase Y, due to carboxyl-terminal digestion. The reason for the resistance to cleavage of TrxR in its oxidized state could be that the COOH-terminal part is sterically protected in the oxidized enzyme but not in the reduced form. Also, analysis of calf thymus or rat liver TrxR with nonreducing SDS gel electrophoresis revealed no species with higher apparent molecular mass than 58 kDa, ruling out the possibility of intermolecular covalent bonds in the oxidized dimeric holoenzyme, that could otherwise possibly include the Cys or SeCys residues at the COOH-terminal end (and also affect cleavage with carboxypeptidase). However, the most likely explanation is that the SeCys residue forms a redox active bridge with the neighboring Cys residue, as also discussed by both Williams and co-workers (32) and Stadtman and co-workers (44). When such a Cys-SeCys bridge is present in the oxidized form of the enzyme, next to the COOH-terminal Gly residue, this is not a substrate for carboxypeptidase-catalyzed cleavage. It has long been known that the nature of the residues at the NH2-terminal side of the most carboxyl-terminal residue to be cleaved by carboxypeptidases may affect the affinity of the protease for its substrate (45). In this context, it should also be noted that inactivation of TrxR with low molecular weight electrophilic compounds like 1-chloro-2,4-dinitrobenzene (23) or 1,3-bis-(2-chloroethyl)-1-nitrosourea (32) is fast in the presence of NADPH but negligible in the absence of NADPH. These observations favor the notion of a Cys-SeCys bridge in the oxidized enzyme (nonaccessible for alkylation), provided that these postulated redox active residues in their reduced state indeed are the targets for the inactivation, which has not yet been conclusively shown.

Furthermore, it should be commented that in the amino acid analysis of residues liberated upon carboxypeptidase Y treatment of reduced TrxR, Gly and SeCys could be identified by co-elution with standards and increasing with time. After 24 h of incubation, a small peak co-eluting with Cys could be detected. However, one compound, also increasing in amount by time of incubation, was not co-eluting with any of the standards. This compound (X in Fig. 3) could possibly indicate the presence of sulfenic or selenenic acid at this site or some other modification of one of the residues at the COOH terminus. However, further studies are needed to investigate this possibility.

Interestingly, Trx reduction was impaired to a greater extent than DTNB reduction upon treatment of TrxR with carboxypeptidase Y (Fig. 2B). A possible explanation for this difference could be that DTNB may be reduced directly by the glutathione reductase-like active site disulfide in the NH2-terminal part of the enzyme, in addition to reduction via the selenocysteine-containing COOH-terminal redox active site, whereas Trx only can be reduced by the latter.

The COOH-terminal elongation may possibly explain the wide substrate specificity of mammalian TrxR compared with glutathione reductase or lipoamide dehydrogenase, suggesting that the redox-active Cys-SeCys couple at the COOH-terminal end is highly accessible when reduced. With the overall structure as well as the mechanism otherwise being similar to glutathione reductase, it may be proposed that the NH2-terminally positioned redox-active disulfide of one subunit in the dimeric holoenzyme is reduced by NADPH via the flavin of the same polypeptide chain, thereafter interacting with the COOH-terminal Cys-SeCys couple of the other subunit. The interface region that governs the association of the two subunits in the glutathione reductase enzyme family is highly conserved also in TrxR, and the dimeric holoenzymes of this enzyme family all associate with the subunits inverted with respect to each other, so that the NH2-terminal end of one subunit interacts with the COOH terminus of the other (1). The additional redox-active disulfide at the COOH-terminal end of mercuric reductase (1, 46) is highly analogous to the proposed Cys-SeCys redox active couple in TrxR. Interestingly, two genes of Plasmodium falciparum were recently identified to encode for a glutathione reductase (47) and a thioredoxin reductase (48); and while both are homologous in sequence to human glutathione reductase and TrxR (49), only the thioredoxin reductase has a COOH-terminal elongation. Although this seems to contain no SeCys residue, a potential redox-active Cys-Gly-Gly-Gly-Lys-Cys motif is found in this elongated part of the enzyme. Moreover, in data base searches, two different genes of Caenorhabditis elegans are found, both highly homologous to mammalian TrxR but one3 with a Gly-Cys-Cys-Gly motif at the COOH terminus and one5 with an open reading frame that could possibly translate into Gly-Cys-SeCys-Gly at the COOH terminus, provided that TGA would translate as SeCys and TAA terminating translation (as in the case of mammalian TrxR). It is not certain that these genes actually are translated in this manner, but if so, C. elegans would thereby have two proteins similar to mammalian TrxR, both with potential redox active motifs at the COOH terminus but one with a Cys-Cys couple and one with a Cys-SeCys couple. The COOH-terminal ends of these proteins are aligned in Table II. The function and importance of the potential redox-active residues indicated certainly deserves further study.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Carboxyl-terminal parts of enzymes related to mammalian TrxR

Unlike human TrxR, the rat enzyme contained a potential asparagine-linked oligosaccharide attachment site, Asn2-Asp3-Ser4. The corresponding human sequence was Asn2-Gly3-Pro4, and it was recently shown that glycosyl groups could not be detected in TrxR of human cell lines (44), while this is not clear for the rat enzyme. We found that bovine TrxR had a blocked NH2 terminus. However, NH2-terminal sequence determination was possible after treatment of the protein with acetic acid, with the sequence starting at a position corresponding to the fifth residue of the predicted human and rat amino acid sequences. NH2-terminal sequence determination of the human enzyme was earlier reported to reveal a sequence starting two residues COOH-terminally of the proposed initiating methionine (26). The explanation of these inconclusive findings regarding the NH2 terminus of the enzyme is not established. The results may indicate a blocked NH2 terminus, which possibly is easily degraded during purification. Alternatively, the results may reflect NH2-terminal heterogeneity of the enzyme, purified from several different sources. Attached carbohydrates and NH2-terminal heterogeneities could perhaps explain some of the differences in estimations of molecular mass of mammalian TrxR, reported to be 54,171 Da (predicted) (26), 55 kDa (24), 57 kDa (25), 58 kDa (12), or 60 kDa (13). Interestingly, COS cells transfected with a human TrxR cDNA construct4 produced three different recombinant proteins with molecular masses of ~55-60 kDa, detected using polyclonal antibodies and Western blotting, while nontransfected lung adenocarcinoma cells only contained a 55-kDa protein, detected using the same antibodies (33). The larger proteins in the transfected COS cells could represent nonnatural products due to overexpression, but still the question of heterogeneities in the NH2-terminal region of mammalian TrxR and the possible existence of isoenzymes has to be studied further.

In conclusion, mammalian TrxR is a recently discovered selenoprotein with a structure closely related to glutathione reductase. The larger size is due to a COOH-terminal elongation with a conserved selenocysteine-containing motif (Gly-Cys-SeCys-Gly), which we show is redox-active and which may explain the exceptionally wide substrate specificity of the enzyme and its inhibition by some clinically used drugs.

    ACKNOWLEDGEMENTS

The help of Lena Hernberg with amino acid sequencing, Carina Palmberg with determination of amino acid composition, and Dr. Yuanli with initial predictions of secondary structural motifs is greatly acknowledged. We also acknowledge helpful discussions with Drs. Yair Aharonowitz, Thressa Stadtman, and Charles Williams, Jr.

    FOOTNOTES

* This study was supported by the Swedish Cancer Society (projects 961, 3628-B96-02PAA, and 3775-B96-01XAB), the Swedish Medical Research Council (project 13X-3529), the Wallenberg Foundation, and the Medical Faculty of the Karolinska Institute.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) U63923.

Dagger These two authors contributed equally to this paper.

§ To whom correspondence should be addressed. Tel.: 46-8-728-76-86; Fax: 46-8-728-47-16.

1 The abbreviations used are: TrxR, thioredoxin reductase; Trx, thioredoxin; TpR, trypanothione reductase; DTNB, 5,5'-dithiobis(2-nitrobenzoic acid); 3'-UTR, 3'-untranslated region; SECIS, selenocysteine insertion sequence; SeCys or U, selenocysteine; DTT, dithiothreitol; HPLC, high pressure liquid chromatography.

2 N. H. Lee, K. G. Weinstock, E. F. Kirkness, J. A. Earle-Hughes, R. A. Fuldner, S. Marmaras, A. Glodek, J. D. Gocayne, M. O. Adams, A. R. Kerlavage, C. M. Fraser, and J. C. Venter, GenBankTM accession number H34190.

3 J. Sulston, Z. Du, K. Thomas, R. Wilson, L. Hillier, R. Staden, N. Halloran, P. Green, J. Thierry-Mieg, L. Qiu, and S. Dear, Swiss-Prot accession number .

4 A cDNA clone derived from a human bone marrow-derived stromal cell line of which the sequence was essentially identical to that of the earlier published human placental TrxR cDNA was studied but was mistaken as encoding a novel oxidoreductase (33), probably since the sequence of the human TrxR had not yet been entered into the data base. This has also been noted (30).

5 R. Wilson, R. Ainscough, K. Anderson, C. Baynes, M. Berks, J. Bonfield, J. Burton, M. Connell, et al., GenBankTM, accession number U61947 (gene C06G3).

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Williams, C. H., Jr. (1992) in Chemistry and Biochemistry of Flavoenzymes (Müller, F., ed), pp. 121-211, CRC Press, Inc., Boca Raton, FL
  2. Holmgren, A. (1985) Annu. Rev. Biochem. 54, 237-271[CrossRef][Medline] [Order article via Infotrieve]
  3. Holmgren, A., and Björnstedt, M. (1995) Methods Enzymol. 252, 199-208[CrossRef][Medline] [Order article via Infotrieve]
  4. Holmgren, A. (1989) J. Biol. Chem. 264, 13963-13966[Free Full Text]
  5. Yodoi, J., and Tursz, T. (1991) Adv. Cancer Res. 57, 381-411[Medline] [Order article via Infotrieve]
  6. Holmgren, A. (1995) Structure 3, 239-243[Medline] [Order article via Infotrieve]
  7. Powis, G., Briehl, M., and Oblong, J. (1995) Pharmacol. Ther. 68, 149-173[CrossRef][Medline] [Order article via Infotrieve]
  8. Waksman, G., Krishna, T. S., Williams, C. H., Jr., and Kuriyan, J. (1994) J. Mol. Biol. 236, 800-816[CrossRef][Medline] [Order article via Infotrieve]
  9. Kuriyan, J., Krishna, T. S. R., Wong, L., Guenther, B., Pahler, A., Williams, C. H., Jr., and Model, P. (1991) Nature 352, 172-174[CrossRef][Medline] [Order article via Infotrieve]
  10. Dai, S., Saarinen, M., Ramaswamy, S., Meyer, Y., Jacquot, J. P., and Eklund, H. (1996) J. Mol. Biol. 264, 1044-1057[CrossRef][Medline] [Order article via Infotrieve]
  11. Holmgren, A. (1977) J. Biol. Chem. 252, 4600-4606[Medline] [Order article via Infotrieve]
  12. Luthman, M., and Holmgren, A. (1982) Biochemistry 21, 6628-6633[Medline] [Order article via Infotrieve]
  13. Oblong, J. E., Gasdaska, P. Y., Sherrill, K., and Powis, G. (1993) Biochemistry 32, 7271-7277[Medline] [Order article via Infotrieve]
  14. Arnér, E. S. J., Nordberg, J., and Holmgren, A. (1996) Biochem. Biophys. Res. Commun. 225, 268-274[CrossRef][Medline] [Order article via Infotrieve]
  15. Björnstedt, M., Kumar, S., and Holmgren, A. (1992) J. Biol. Chem. 267, 8030-8034[Abstract/Free Full Text]
  16. Kumar, S., Björnstedt, M., and Holmgren, A. (1992) Eur. J. Biochem. 207, 435-39[Abstract]
  17. Holmgren, A., and Lyckeborg, C. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 5149-5152[Abstract]
  18. Björnstedt, M., Hamberg, M., Kumar, S., Xue, J., and Holmgren, A. (1995) J. Biol. Chem. 270, 11761-11764[Abstract/Free Full Text]
  19. Mau, B.-L., and Powis, G. (1992) Biochem. Pharmacol. 43, 1613-1620[CrossRef][Medline] [Order article via Infotrieve]
  20. Mau, B.-L., and Powis, G. (1992) Biochem. Pharmacol. 43, 1621-1627[Medline] [Order article via Infotrieve]
  21. Schallreuter, K. U., Gleason, F. K., and Wood, J. M. (1990) Biochim. Biophys. Acta 1054, 14-20[CrossRef][Medline] [Order article via Infotrieve]
  22. Schallreuter, K. U., and Wood, J. M. (1989) Biochem. Biophys. Res. Commun. 160, 573-579[Medline] [Order article via Infotrieve]
  23. Arnér, E. S. J., Björnstedt, M., and Holmgren, A. (1995) J. Biol. Chem. 270, 3479-3482[Abstract/Free Full Text]
  24. Gladyshev, V. N., Jeang, K.-T., and Stadtman, T. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6146-6151[Abstract/Free Full Text]
  25. Tamura, T., and Stadtman, T. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 1006-1011[Abstract/Free Full Text]
  26. Gasdaska, P. Y., Gasdaska, J. R., Cochran, S., and Powis, G. (1995) FEBS Lett. 373, 5-9[CrossRef][Medline] [Order article via Infotrieve]
  27. Holmgren, A., Arnér, E., Åslund, F., Björnstedt, M., Liangwei, Z., Ljung, J., Nakamura, H., and Nikitovic, D. (1997) in Oxidative Stress in Cancer, AIDS and Neurodegenerative Diseases (Montagnier, R., Olivier, L., and Pasquier, C., eds), pp. 229-246, Marcel Dekker, Inc., New York
  28. Ren, X., Björnstedt, M., Shen, B., Ericson, M. L., and Holmgren, A. (1993) Biochemistry 32, 9701-9708[Medline] [Order article via Infotrieve]
  29. Björkman, L., Langworth, S., Lind, B., Elinder, C.-G., and Nordberg, M. (1993) J. Trace Elem. Electrolytes Health Dis. 7, 157-164[Medline] [Order article via Infotrieve]
  30. Miranda-Vizuete, A., and Spyrou, G. (1997) Biochem. J. 325, 287-288[Medline] [Order article via Infotrieve]
  31. Lee, N. H., Weinstock, K. G., Kirkness, E. F., Earle-Hughes, J. A., Fuldner, R. A., Marmaras, S., Glodek, A., Gocayne, J. D., Adams, M. D., Kerlavage, A. R., Fraser, C. M., and Venter, J. C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8303-8307[Abstract]
  32. Arscott, L. D., Gromer, S., Schirmer, R. H., Becker, K., and Williams, C. H., Jr. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3621-3626[Abstract/Free Full Text]
  33. Koishi, R., Kawashima, I., Yoshimura, C., Sugawara, M., and Serizawa, N. (1997) J Biol Chem 272, 2570-2577[Abstract/Free Full Text]
  34. Shen, Q., Chu, F. F., and Newburger, P. E. (1993) J. Biol. Chem. 268, 11463-11469[Abstract/Free Full Text]
  35. Berry, M. J., Banu, L., Chen, Y., Mandel, S. J., Kieffer, J. D., Harney, J. W., and Larsen, P. R. (1991) Nature 353, 273-276[CrossRef][Medline] [Order article via Infotrieve]
  36. Berry, M. J., Banu, L., Harney, J. W., and Larsen, P. R. (1993) EMBO J. 12, 3315-3322[Abstract]
  37. Hill, K. E., Lloyd, R. S., and Burk, R. F. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 537-541[Abstract]
  38. Stadtman, T. C. (1996) Annu. Rev. Biochem. 65, 83-100[CrossRef][Medline] [Order article via Infotrieve]
  39. Low, S. C., and Berry, M. J. (1996) Trends Biochem. Sci. 21, 203-208[CrossRef][Medline] [Order article via Infotrieve]
  40. Walczak, R., Westhof, E., Carbon, P., and Krol, A. (1996) RNA 2, 367-379[Abstract]
  41. Gromer, S., Schirmer, R. H., and Becker, K. (1997) FEBS Lett. 412, 318-320[CrossRef][Medline] [Order article via Infotrieve]
  42. Hill, K. E., McCollum, G. W., Boeglin, M. E., and Burk, R. F. (1997) Biochem. Biophys. Res. Commun. 234, 293-295[CrossRef][Medline] [Order article via Infotrieve]
  43. Forstrom, J. W., Zakowski, J. J., and Tappel, A. L. (1978) Biochemistry 17, 2639-2644[Medline] [Order article via Infotrieve]
  44. Liu, S. Y., and Stadtman, T. C. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6138-6141[Abstract/Free Full Text]
  45. Abramowitz, N., Schechter, I., and Berger, A. (1967) Biochem. Biophys. Res. Commun. 26, 862-867[Medline] [Order article via Infotrieve]
  46. Miller, S. M., Moore, M. J., Massey, V., Williams, C. H., Jr., Distefano, M., Ballou, D. P., and Walsh, C. T. (1989) Biochemistry 28, 1194-1205[Medline] [Order article via Infotrieve]
  47. Färber, P. M., Becker, K., Müller, S., Schirmer, R. H., and Franklin, R. M. (1996) Eur. J. Biochem. 239, 655-661[Abstract]
  48. Müller, S., Gilberger, T. W., Färber, P. M., Becker, K., Schirmer, R. H., and Walter, R. D. (1996) Mol. Biochem. Parasitol. 80, 215-219[CrossRef][Medline] [Order article via Infotrieve]
  49. Becker, K., Färber, P. M., von der Lieth, C.-M., and Müller, S. (1997) in Flavins and flavoproteins (Stevenson, K. J., Massey, V., and Williams, C. H., Jr., eds), University Press, Calgary
  50. Wilson, R., Ainscough, R., Anderson, K., Baynes, C., Berks, M., Bonfield, J., Burton, J., Connell, M., et al.. (1994) Nature 368, 32-38[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.